246 related articles for article (PubMed ID: 27572319)
1. Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer.
Trott JF; Kim J; Abu Aboud O; Wettersten H; Stewart B; Berryhill G; Uzal F; Hovey RC; Chen CH; Anderson K; Graef A; Sarver AL; Modiano JF; Weiss RH
Oncotarget; 2016 Oct; 7(41):66540-66557. PubMed ID: 27572319
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
Sumitomo M; Takahara K; Zennami K; Nagakawa T; Maeda Y; Shiogama K; Yamamoto Y; Muto Y; Nukaya T; Takenaka M; Fukaya K; Ichino M; Sasaki H; Saito K; Shiroki R
Cancer Sci; 2021 Mar; 112(3):1038-1047. PubMed ID: 33410234
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
[TBL] [Abstract][Full Text] [Related]
5. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
6. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.
Löb S; Königsrainer A; Zieker D; Brücher BL; Rammensee HG; Opelz G; Terness P
Cancer Immunol Immunother; 2009 Jan; 58(1):153-7. PubMed ID: 18418598
[TBL] [Abstract][Full Text] [Related]
7. Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
Riess C; Schneider B; Kehnscherper H; Gesche J; Irmscher N; Shokraie F; Classen CF; Wirthgen E; Domanska G; Zimpfer A; Strüder D; Junghanss C; Maletzki C
Front Immunol; 2020; 11():55. PubMed ID: 32117235
[TBL] [Abstract][Full Text] [Related]
8. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma.
Riesenberg R; Weiler C; Spring O; Eder M; Buchner A; Popp T; Castro M; Kammerer R; Takikawa O; Hatz RA; Stief CG; Hofstetter A; Zimmermann W
Clin Cancer Res; 2007 Dec; 13(23):6993-7002. PubMed ID: 18056175
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of indoleamine 2,3-dioxygenase by stereoisomers of 1-methyl tryptophan in an experimental graft-versus-tumor model.
Lim JY; Lee SE; Park G; Choi EY; Min CK
Exp Hematol; 2014 Oct; 42(10):862-6.e3. PubMed ID: 24971697
[TBL] [Abstract][Full Text] [Related]
10. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
[TBL] [Abstract][Full Text] [Related]
11. The expanding roles of 1-methyl-tryptophan (1-MT): in addition to inhibiting kynurenine production, 1-MT activates the synthesis of melatonin in skin cells.
Moreno AC; Clara RO; Coimbra JB; Júlio AR; Albuquerque RC; Oliveira EM; Maria-Engler SS; Campa A
FEBS J; 2013 Oct; 280(19):4782-92. PubMed ID: 23879623
[TBL] [Abstract][Full Text] [Related]
12. IDO Targeting in Sarcoma: Biological and Clinical Implications.
Nafia I; Toulmonde M; Bortolotto D; Chaibi A; Bodet D; Rey C; Velasco V; Larmonier CB; Cerf L; Adam J; Le Loarer F; Savina A; Bessede A; Italiano A
Front Immunol; 2020; 11():274. PubMed ID: 32194552
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation.
Miyazaki T; Moritake K; Yamada K; Hara N; Osago H; Shibata T; Akiyama Y; Tsuchiya M
J Neurosurg; 2009 Aug; 111(2):230-7. PubMed ID: 19199463
[TBL] [Abstract][Full Text] [Related]
14. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
[TBL] [Abstract][Full Text] [Related]
15. Psychological stress-induced, IDO1-dependent tryptophan catabolism: implications on immunosuppression in mice and humans.
Kiank C; Zeden JP; Drude S; Domanska G; Fusch G; Otten W; Schuett C
PLoS One; 2010 Jul; 5(7):e11825. PubMed ID: 20689575
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
Hou DY; Muller AJ; Sharma MD; DuHadaway J; Banerjee T; Johnson M; Mellor AL; Prendergast GC; Munn DH
Cancer Res; 2007 Jan; 67(2):792-801. PubMed ID: 17234791
[TBL] [Abstract][Full Text] [Related]
17. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
[TBL] [Abstract][Full Text] [Related]
18. In vivo metabolism of tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1.
Zitron IM; Kamson DO; Kiousis S; Juhász C; Mittal S
Cancer Biol Ther; 2013 Apr; 14(4):333-9. PubMed ID: 23358471
[TBL] [Abstract][Full Text] [Related]
19. Alterations in the metabolism of tryptophan in patients with chronic hepatitis C six months after pegylated interferon-α 2a treatment.
Pawlowski T; Malyszczak K; Inglot M; Zalewska M; Radkowski M; Laskus T; Pawlak D
Psychoneuroendocrinology; 2018 Nov; 97():1-7. PubMed ID: 29990677
[TBL] [Abstract][Full Text] [Related]
20. Apicomplexan parasite, Eimeria falciformis, co-opts host tryptophan catabolism for life cycle progression in mouse.
Schmid M; Lehmann MJ; Lucius R; Gupta N
J Biol Chem; 2012 Jun; 287(24):20197-207. PubMed ID: 22535959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
